BLFS Biolife Solutions

BioLife Solutions, Inc. engages in the development, manufacture and marketing of biopreservation tools for cells and tissues. Its product offerings include proprietary hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs, generic blood stem cell freezing and cell thawing media products and custom product formulation and custom packaging services. The company was founded by Boris Rubinsky in 1987 and is headquartered in Bothell, WA.
Company profile
Ticker
BLFS
Exchange
Website
CEO
Michael Rice
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Medtronic • Varian Medical Systems • Conmed • Natus Medical • Masimo • LivaNova • Outset Medical • Fonar • Cutera • Inmode ...
Former names
CRYOMEDICAL SCIENCES INC
SEC CIK
Corporate docs
IRS number
943076866
BLFS stock data
()
News
The Daily Biotech Pulse: Dynavax-Clover Start Phase 2/3 Vaccine Study. BrainStorm Reports Positive MS Readout, NeoGenomics Goes Shopping
24 Mar 21
12 Health Care Stocks Moving In Tuesday's Intraday Session
23 Mar 21
Stocks That Hit 52-Week Highs On Tuesday
23 Mar 21
Benzinga's Top Ratings Upgrades, Downgrades For March 23, 2021
23 Mar 21
The Daily Biotech Pulse: FDA Approvals For Merck, Pacira And Zealand, Roche-Regeneron Ace Late-Stage COVID-19 Study, AlloVir Appoints Gilead Virology Chief As CEO
23 Mar 21
Press releases
BioLife Solutions Appoints Two New Independent Board Directors
6 Apr 21
Stirling Ultracold to Merge with BioLife Solutions, the Leader in Gene and Cell Therapy Bioproduction Tools and Services
22 Mar 21
BioLife Solutions Announces Fourth Quarter and Full Year 2020 Financial Results
22 Mar 21
Stirling Ultracold Announces Merger Agreement with BioLife Solutions to Further Support Life-Science Industry with Expertise in Ultra-Low Temperature Storage
22 Mar 21
BioLife Solutions to Acquire Stirling Ultracold in an All-Stock Merger
22 Mar 21
Calendar
31 Mar 21
13 Apr 21
31 Dec 21
Financial summary
Quarter (USD) |
Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) |
Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Financial data from company earnings reports.
Cash burn rate (estimated) | Burn method: Change in cash | Burn method: Operating income/loss | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 90.46M | 90.46M | 90.46M | 90.46M | 90.46M | 90.46M |
Cash burn (monthly) | 6.18M | (positive/no burn) | 1.8M | 59.17K | (positive/no burn) | (positive/no burn) |
Cash used (since last report) | 21.24M | n/a | 6.18M | 203.31K | n/a | n/a |
Cash remaining | 69.22M | n/a | 84.28M | 90.25M | n/a | n/a |
Runway (months of cash) | 11.2 | n/a | 46.9 | 1525.4 | n/a | n/a |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
8 Apr 21 | Marcus Schulz | Common Stock | Sell | Dispose S | No | No | 35.77 | 224 | 8.01K | 39,795 |
8 Apr 21 | Rice Michael | Common Stock | Sell | Dispose S | No | Yes | 35.32 | 11,461 | 404.8K | 262,527 |
8 Apr 21 | Rice Michael | Common Stock | Option exercise | Aquire M | No | No | 1.64 | 11,461 | 18.8K | 273,988 |
8 Apr 21 | Rice Michael | Employee Stock Option Common Stock | Option exercise | Dispose M | No | No | 1.64 | 11,461 | 18.8K | 183,382 |
1 Apr 21 | Greef Roderick De | Common Stock | Sell | Dispose S | No | No | 36.53 | 3,855 | 140.82K | 182,316 |
1 Apr 21 | Greef Roderick De | Common Stock | Option exercise | Aquire M | No | No | 0 | 9,932 | 0 | 186,171 |
1 Apr 21 | Rice Michael | Common Stock | Sell | Dispose S | No | No | 36.53 | 10,149 | 370.74K | 262,527 |
1 Apr 21 | Rice Michael | Common Stock | Option exercise | Aquire M | No | No | 0 | 26,154 | 0 | 272,676 |
1 Apr 21 | Aby J. Mathew | Common Stock | Sell | Dispose S | No | No | 36.53 | 4,020 | 146.85K | 200,981 |
1 Apr 21 | Aby J. Mathew | Common Stock | Option exercise | Aquire M | No | No | 0 | 10,358 | 0 | 211,339 |
Institutional ownership Q4 2020
Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.
73.9% owned by funds/institutions
13F holders |
Current |
---|---|
Total holders | 125 |
Opened positions | 36 |
Closed positions | 14 |
Increased positions | 28 |
Reduced positions | 45 |
13F shares |
Current |
---|---|
Total value | 1.65B |
Total shares | 24.2M |
Total puts | 52.8K |
Total calls | 101.2K |
Total put/call ratio | 0.5 |
Largest owners |
Shares | Value |
---|---|---|
Casdin Capital | 7.44M | $296.79M |
Wasatch Advisors | 1.34M | $53.3M |
Vanguard | 1.28M | $51.03M |
BLK Blackrock | 1.23M | $49.17M |
Marshall Wace | 1.16M | $46.34M |
Ranger Investment Management | 989.51K | $39.47M |
AMP Ameriprise Financial | 916.88K | $36.58M |
Royce & Associates | 845.12K | $33.71M |
Russell Investments | 840.64K | $33.55M |
TimesSquare Capital Management | 516.1K | $20.59M |
Content analysis
?
Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
Abbott, accuracy, administer, advanced, Aebersold, alter, antitrust, Aramark, basket, Belimed, biopharma, Biostorage, budget, burdensome, calibrated, cap, CGT, checking, children, coaching, companywide, customary, directionally, distancing, domestic, dropped, dynamic, embedded, eventual, feedback, fewer, filer, GCI, GE, hospital, hypothetical, imposition, incorrectly, infection, inspection, instrument, jeopardizing, lab, leave, lowest, machinery, main, maker, mandated, MCG, merge, merged, moment, month, NaN, opposite, outlook, overhang, PanTHERA, payoff, pendency, permissible, perpetual, physically, portrayed, premier, prepaid, progression, prolonged, proposition, receipt, recession, reinforce, repayable, Rescue, resumed, rolling, Sarah, scenario, Schulz, SciSafe, segregated, short, situation, Southwest, specimen, spite, staying, steeply, strain, subsided, symptom, transmissible, transmission, uncured, underwriter, underwriting, Undiscovered, unemployment, unprecedented, unwanted, vertical, virulent, waiting, waived, whistleblower, workforce, worn
Removed:
amend, barrier, certificate, classification, comparability, deficit, delivered, designate, detection, deteriorate, discourage, distributor, email, enhanced, entry, freely, fundamental, history, inadequate, incorporation, interested, investee, landlord, largely, Lessor, open, pertain, phone, premium, prevailing, redeemed, registering, representation, restated, retrospective, secured, summarized, takeover, tradable, transparency, turn, unchanged, unsolicited
Financial reports
10-K
2020 FY
Annual report
31 Mar 21
10-Q
2020 Q3
Quarterly report
9 Nov 20
10-Q
2020 Q2
Quarterly report
10 Aug 20
10-K/A
2019 FY
Annual report (amended)
18 Jun 20
10-Q
2020 Q1
Quarterly report
29 May 20
10-K
2019 FY
Annual report
15 May 20
NT 10-K
Notice of late annual filing
30 Apr 20
10-Q
2019 Q3
Quarterly report
12 Nov 19
10-Q
2019 Q2
Quarterly report
9 Aug 19
10-Q
2019 Q1
Quarterly report
9 May 19
Current reports
8-K
BioLife Solutions Appoints Two New
7 Apr 21
8-K
Entry into a Material Definitive Agreement
25 Mar 21
8-K
BioLife Solutions Announces Fourth Quarter and Full Year 2020 Financial Results
22 Mar 21
8-K
Departure of Directors or Certain Officers
17 Feb 21
8-K
Departure of Directors or Certain Officers
7 Jan 21
8-K/A
Financial Statements and Exhibits
14 Dec 20
8-K
Departure of Directors or Certain Officers
7 Dec 20
8-K
Other Events
1 Dec 20
8-K
Departure of Directors or Certain Officers
30 Nov 20
8-K
BioLife Solutions Announces Third Quarter 2020 Financial Results
5 Nov 20
Registration and prospectus
424B5
Prospectus supplement for primary offering
6 Jul 20
424B5
Prospectus supplement for primary offering
1 Jul 20
S-3
Shelf registration
24 Sep 19
S-3/A
Shelf registration (amended)
20 Mar 18
S-3/A
Shelf registration (amended)
4 Feb 18
S-3
Shelf registration
4 Jan 18
S-8
Registration of securities for employees
4 Jan 18
S-3
Shelf registration
7 Jan 16
S-8
Registration of securities for employees
18 Jun 15
424B3
Prospectus supplement
8 Jan 15
Proxies
DEF 14A
Definitive proxy
29 May 20
DEF 14A
Definitive proxy
30 Apr 19
DEF 14A
Definitive proxy
5 Apr 18
DEF 14A
Definitive proxy
13 Apr 17
DEF 14A
Definitive proxy
29 Mar 16
DEF 14A
Definitive proxy
23 Mar 15
DEFA14A
Additional proxy soliciting materials
23 Mar 15
DEF 14A
Definitive proxy
19 Jun 14
DEF 14C
Information statement
26 Dec 13
PRE 14C
Preliminary information
15 Dec 13
Other
EFFECT
Notice of effectiveness
7 Oct 19
CORRESP
Correspondence with SEC
1 Oct 19
UPLOAD
Letter from SEC
1 Oct 19
EFFECT
Notice of effectiveness
10 Apr 18
CORRESP
Correspondence with SEC
9 Apr 18
UPLOAD
Letter from SEC
16 Dec 16
CORRESP
Correspondence with SEC
8 Dec 16
UPLOAD
Letter from SEC
16 Nov 16
EFFECT
Notice of effectiveness
14 Jan 16
CORRESP
Correspondence with SEC
11 Jan 16
Ownership
4
BIOLIFE SOLUTIONS / Michael Rice ownership change
12 Apr 21
4
BIOLIFE SOLUTIONS / Marcus Schulz ownership change
12 Apr 21
3
BIOLIFE SOLUTIONS / Rachel Ellingson ownership change
8 Apr 21
3
BIOLIFE SOLUTIONS / Amy DuRoss ownership change
8 Apr 21
4
BIOLIFE SOLUTIONS / Karen A. Foster ownership change
5 Apr 21
4
BIOLIFE SOLUTIONS / Aby J. Mathew ownership change
5 Apr 21
4
BIOLIFE SOLUTIONS / Todd Berard ownership change
5 Apr 21
4
BIOLIFE SOLUTIONS / GREEF RODERICK DE ownership change
5 Apr 21
4
BIOLIFE SOLUTIONS / Michael Rice ownership change
5 Apr 21
4
BIOLIFE SOLUTIONS / Aby J. Mathew ownership change
30 Mar 21
Patents
GRANT
Utility
Systems, devices, and methods for automated sample thawing
9 Feb 21
The present invention generally relates to thawing a cryogenically frozen sample.
APP
Utility
Wound Sealing Powder
12 Aug 20
A wound sealing powder, method of making a wound sealing powder, and method of using a wound sealing powder to reduce blood flow from a wound are provided.
GRANT
Utility
Portable thawer components and features
3 Aug 20
The present disclosure is related to sample thawing.
GRANT
Utility
Systems, devices, and methods for automated sample thawing
3 Feb 20
The present invention generally relates to thawing a cryogenically frozen sample.
GRANT
Utility
Cryogenic workstation using nitrogen
13 Jan 20
Cryogenic devices are provided in which liquid nitrogen is used to maintain ultra-low temperatures in which samples can be manipulated.
Transcripts
2020 Q4
Earnings call transcript
23 Mar 21
2020 Q3
Earnings call transcript
8 Nov 20
2020 Q2
Earnings call transcript
9 Aug 20
2020 Q1
Earnings call transcript
14 May 20
2019 Q4
Earnings call transcript
11 Mar 20
2019 Q3
Earnings call transcript
12 Nov 19
2019 Q2
Earnings call transcript
8 Aug 19
2019 Q1
Earnings call transcript
9 May 19
2018 Q4
Earnings call transcript
14 Mar 19
2018 Q3
Earnings call transcript
9 Nov 18
Reddit threads
Here is a Market Recap for today Tuesday, March 23, 2021
23 Mar 21
Here is a Market Recap for today Tuesday, March 23, 2021
23 Mar 21
Game Plan For March 23, 2021
23 Mar 21
Morning Update for Tuesday, 03/23/21
23 Mar 21
Daily Discussion Thread - March 22nd, 2021
22 Mar 21
Stock Earnings for 22 to 26 March 2021
21 Mar 21
Wall Street Week Ahead for the trading week beginning March 22nd, 2021
20 Mar 21
Daily Discussion Thread - March 19th, 2021
19 Mar 21
Daily Discussion Thread - March 10th, 2021
10 Mar 21
Daily Discussion Thread - March 9th, 2021
9 Mar 21